生物技术公司Sensei Biotherapeutics, Inc. (SNSE) 宣布,其候选药物Piktor在针对HR阳性、HER2阴性(HR+/HER2-)晚期乳腺癌患者的1B/2期临床试验中,已完成对首位患者的给药。这一进展标志着该药物临床开发项目进入了新的阶段。
生物技术公司Sensei Biotherapeutics, Inc. (SNSE) 宣布,其候选药物Piktor在针对HR阳性、HER2阴性(HR+/HER2-)晚期乳腺癌患者的1B/2期临床试验中,已完成对首位患者的给药。这一进展标志着该药物临床开发项目进入了新的阶段。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.